Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Phase 1

Recruiting

Conditions: Refractory Malignant Ascites

Interventions: Drug: H101
Drug: Tislelizumab

First Posted Date: 2022-03-31

Last Posted Date: 2023-04-12

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05303844

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Phase 2

Conditions: Metastatic Breast Cancer in the Liver

Interventions: Combination Product: Cryoablation Combined with Tirelizumab and Bevacizumab

First Posted Date: 2022-03-31

Last Posted Date: 2022-06-09

Lead Sponsor: Fudan University

Target Recruit Count: 15

Registration Number: NCT05303038

Locations: 🇨🇳
Fudan University Shangshai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-point

Not Applicable

Completed

Conditions: Serratus Anterior Plane Block
Mammary Cancer
Postoperative Pain

Interventions: Procedure: Double-point SAPB
Procedure: Single-point SAPB

First Posted Date: 2022-03-28

Last Posted Date: 2024-03-06

Lead Sponsor: Fudan University

Target Recruit Count: 57

Registration Number: NCT05299021

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

ZR-CHOP in DLBCL With Specific Gene Abnormality

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: zanubrutinib

First Posted Date: 2022-03-22

Last Posted Date: 2022-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 62

Registration Number: NCT05290337

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2022-03-15

Last Posted Date: 2023-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 128

Registration Number: NCT05281003

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Phase 2

Conditions: VEGFR-TKI
Carcinosarcoma
Sarcomatoid Carcinoma
PD-1 Immunotherapy

Interventions: Drug: Camrelizumab Combined With Apatinib

First Posted Date: 2022-03-04

Last Posted Date: 2022-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT05265793

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Carcinoma

Interventions: Drug: Fruquintinib

First Posted Date: 2022-02-25

Last Posted Date: 2022-02-25

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT05257122

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: R-CDOP+intrathecal MTX

First Posted Date: 2022-02-25

Last Posted Date: 2024-11-11

Lead Sponsor: Fudan University

Target Recruit Count: 83

Registration Number: NCT05257018

Locations: 🇨🇳
Cancer Hospital affilicaited to Xinjiang Medical University, Ürümqi, Xinjiang, China
🇨🇳
Dongmei Ji, Shanghai, Shanghai, China

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2

Recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Capecitabine combined with lenvatinib and tislelizumab

First Posted Date: 2022-02-24

Last Posted Date: 2022-04-04

Lead Sponsor: Fudan University

Target Recruit Count: 75

Registration Number: NCT05254847

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Phase 2

Recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Furmonertinib (160mg)

First Posted Date: 2022-02-24

Last Posted Date: 2022-08-04

Lead Sponsor: Fudan University

Target Recruit Count: 62

Registration Number: NCT05255406

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy